RxDoctor Payments Data

Makena Turner, PA

Physician Assistant · Spokane, WANPI 1093306169

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.1% of the total across 916 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.3% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,705in general payments, 2019–2025

Across 916 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Novartis$1K
  • Pfizer$1K
  • E.r. Squibb & Sons, L.L.C.$985
  • Bristol Myers Squibb$873
  • AstraZeneca$741
  • plus $13K from 54 others

What the payments were for

  • Food & beverage$18,34393%
  • Education$1,3627%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)82$1,644
Novartis72$1,274
Pfizer66$1,006
E.r. Squibb & Sons, L.L.C.62$985
Bristol Myers Squibb48$873
AstraZeneca(2 entities)32$741
Incyte Corporation33$731
AbbVie25$708
Merck30$704
Seagen Inc.21$641
Astellas Pharma US Inc22$607
Genentech USA, Inc.32$585
Amgen23$523
Lilly USA, LLC19$492
Pharmacyclics LLC, An Abbvie Company20$487
Takeda Pharmaceuticals U.S.A., Inc.16$460
Sanofi18$392
Regeneron Healthcare Solutions, Inc.12$358
Myriad Genetic Laboratories, Inc.25$353
Eisai Inc.17$351
EMD Serono, Inc.11$349
Blueprint Medicines Corporation14$303
Sobi, Inc8$300
Exelixis Inc.12$276
Boehringer Ingelheim11$274
GSK14$267
Tersera Therapeutics LLC9$255
Array Biopharma Inc11$203
Alnylam Pharmaceuticals Inc.9$195
Acrotech Biopharma Inc.9$193
Beigene USA, Inc.7$181
Jazz Pharmaceuticals Inc.8$168
Bayer8$158
Epizyme, Inc.4$147
Gilead(2 entities)6$139
Taiho Oncology, Inc.4$109
Janssen Scientific Affairs, LLC1$106
Immunocore Limited3$98
AVEO Pharmaceuticals, Inc.5$96
Puma Biotechnology, Inc.5$96
Springworks Therapeutics, Inc.4$95
Sanofi-aventis U.S. LLC2$93
Agios Pharmaceuticals, Inc.4$90
Foundation Medicine, Inc.5$85
Stemline Therapeutics Inc.3$85
Deciphera Pharmaceuticals Inc.3$81
Beone Medicines USA, Inc.3$80
Daiichi Sankyo Inc.3$76
Servier Pharmaceuticals LLC4$76
Iovance Biotherapeutics, Inc.2$76
Sun Pharmaceutical Industries Inc.3$71
Acceleron Pharma, Inc.3$65
Spectrum Pharmaceuticals Inc.3$61
Morphosys, US Inc.3$58
Pharmacosmos Therapeutics Inc.3$58
Rigel Pharmaceuticals, Inc.2$54
Fresenius Kabi USA, LLC3$53
CTI Biopharma Corp.2$53
Azurity Pharmaceuticals, Inc.2$45
G1 Therapeutics, Inc.2$44

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,705 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$75,148
Medicare patients
44
Services billed
2,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide13$218,575
JakafiRuxolitinib Phosphate15$217,578
EliquisApixaban18$18,427
Enoxaparin Sodium12$5,588
ValacyclovirValacyclovir Hcl16$2,502
Gabapentin25$1,057
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$919
Ondansetron OdtOndansetron54$775
Prochlorperazine Maleate59$619
Acyclovir40$593
Anastrozole46$514
Oxycodone Hcl29$380
Prednisone44$257
Letrozole32$177
Levothyroxine Sodium12$175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$731$217,57815 claims
PfizerEliquis$1,006$18,42718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →